Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ACP1 | P24666 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL31379706 | 0.87 | TACR1 (0.41) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL22462784 | 0.82 | CHRNB2 (0.36) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL21722948 | 0.81 | MRGPRX4 (0.39) | CRHR1MRGPRX4ACHEMEN1ALDH1A1 | |
| SCHEMBL22462898 | 0.81 | MRGPRX4 (0.39) | CRHR1MRGPRX4ACHEMEN1ALDH1A1 | |
| SCHEMBL22462826 | 0.77 | MRGPRX4 (0.37) | MRGPRX4ACHEKMT2A | |
| Trifluoroacetic Acid SCHEMBL21722787 | 0.74 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL22462877 | 0.74 | CYP1A2 (0.41) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL22462915 | 0.70 | CHRNB2 (0.38) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL21722954 | 0.70 | SLC6A4 (0.52) | SLC6A4FFAR1 | |
| Trifluoroacetic Acid SCHEMBL23150549 | 0.70 | MGLL (0.49) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-09-09 | — | — | US | disclosed |
| CN-112867720-A | Novel heterocyclic compounds as monoacylglycerol lipase inhibitors | 豪夫迈·罗氏有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-112469724-A | Novel heterocyclic compounds as monoacylglycerol lipase inhibitors | 豪夫迈·罗氏有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20200308190-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | SLC6A2 4793/4885SLC6A4 4860/4885SLC6A3 4770/4885 |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | SLC6A2 4083/4885SLC6A4 4451/4885SLC6A3 4024/4885 |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | SLC6A2 4730/4885SLC6A4 4796/4885SLC6A3 4811/4885 |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | SLC6A2 4730/4885SLC6A4 4796/4885SLC6A3 4811/4885 |
| US-20200308190-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, MGLL, LPL | SLC6A2 4690/4885SLC6A4 4776/4885SLC6A3 4802/4885 |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | SLC6A2 4730/4885SLC6A4 4796/4885SLC6A3 4811/4885 |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | SLC6A2 4730/4885SLC6A4 4796/4885SLC6A3 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.